BRAF and metastatic colorectal cancer: The pooled analysis of the CRYSTAL and OPUS trials on metastatic colorectal cancer showed that BRAF mutation was not predictive for treatment with cetuximab in KRAS wild-type patients, but indicated poor prognosis (43).